In a significant blow to a prominent online mental health care provider, Cerebral Inc. has agreed to shell out more than $3.6 million due to business practices that promoted the unauthorized distribution of controlled substances. This announcement, delivered by Breon Peace, the United States Attorney for the Eastern District of New York, alongside U.S. Drug Enforcement Administration (DEA) Administrator Anne Millgram, reveals the outcome of a grievance that has put the company under stern scrutiny from 2019 to 2022.
Under a non-prosecution agreement (NPA), Cerebral acceded to forfeit $3,652,000, the settlement dictated by the Office for the Eastern District of New York, which, due to Cerebral's financial state, has deferred an additional fine of $2,922,000. According to the justice department's statement, the fine will be waived after the 30-month agreement term "if Cerebral is in compliance with the NPA and unless the Office determines that Cerebral’s financial performance has changed such that payment of all or a portion of the fine would be warranted."
In the statement obtained by the justice department, United States Attorney Peace remark that "People seeking care for their mental health conditions should receive high-quality care that is not motivated or driven by greed. Cerebral sought to increase its bottom line by increasing the prescription of drugs, including controlled substances that can be highly addictive and dangerous." His commentary draws a stark boundary between patient care and corporate malfeasance, wherein the former was compromised by the latter's pursuit of profit.
For a company like Cerebral, that operates primarily via direct-to-consumer channels, offering treatment for a range of mental health issues, the turn of events echoes a cautionary note on ethical medical practice. Particularly criticized were the prescription practices fostering a 'pill-for-profit' model, as seen in the DEA Administrator Anne Milgram's statement, "Cerebral’s exploitation of telemedicine flexibilities deceived patients who were legitimately seeking medical care, putting them at risk in exchange for profit," which signals the abuse of trust many put into such telehealth services.
Further highlighting the controversy, Cerebral's subscription plans linked access to medications, including Schedule II drugs like Adderall, with patient retention and company profit. Metrics used by Cerebral to monitor prescription rates, such as the Initial Visit Rx Rate and the ADHD Stimulant Rx Metric, were skewed toward encouraging frequent prescriptions rather than meeting actual patient needs. Even when their own clinical advisory board, boasting psychology and psychiatry experts, harbored concerns regarding these metrics, Cerebral prioritized revenue over patient safety by not taking any recommendations before implementing these metrics.
Cerebral's practice of offering financial bonuses to providers who hit prescription targets has ceased, along with the prescriptive measures put in place. Since the investigation, they ceased prescribing controlled substances as of October 2022 and have committed not to in the future. Lastly, the NPA requires full cooperation from Cerebral with ongoing investigations, ensuring their pledge to more scrupulous oversight and ethical operations henceforth.
